About Akari Therapeutics
At the forefront of a differentiated approach to cancer treatment, Akari Therapeutics is a Nasdaq-listed oncology biotechnology company (ticker: AKTX) developing a new class of antibody-drug conjugates (ADCs) built around a novel payload, PH1, that targets RNA splicing rather than the tubulin inhibitors or DNA-damaging agents used by existing ADC programmes. Headquartered in New York, the company operates a proprietary ADC discovery platform designed to generate and optimise candidates against any antigen target of interest.
The lead programme, AKTX-101, is directed at the Trop2 receptor expressed on cancer cells. A proprietary linker enables AKTX-101 to deliver the PH1 payload directly into tumours with the aim of minimising off-target effects, differentiating it from first-generation ADC approaches that rely on tubulin or DNA-damaging payloads. Trop2 is a clinically validated target in multiple solid tumour indications, and Akari's RNA-splicing mechanism of action represents biology not yet exploited by currently approved ADC therapies.
The next-generation ADC discovery platform is engineered to accelerate candidate generation and to tailor individual ADCs to specific oncology applications across multiple antigen targets. By combining a distinctive payload class with a flexible discovery engine, Akari positions itself within the broader precision oncology space as a company pursuing mechanistic differentiation from first-wave ADC programmes as its pipeline advances.
Further information is available at akaritx.com.
